ArticleThe Journal of experimental medicine1995
Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells.
Article in The Journal of experimental medicine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 151 citations in OpenAlex.
- AP-1B regulates interactions of epithelial cells and intraepithelial lymphocytes in the intestine.Cellular and molecular life sciences : CMLS · 2024Article
- The CD6 interactome orchestrates ligand-independent T cell inhibitory signaling.Cell communication and signaling : CCS · 2024Article
- Ligands of CD6: roles in the pathogenesis and treatment of cancer.Frontiers in immunology · 2024Review
- CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies.International journal of molecular sciences · 2023Review
- Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery.Pharmaceutics · 2023Article
- Alcam-a and Pdgfr-α are essential for the development of sclerotome-derived stromal cells that support hematopoiesis.Nature communications · 2023Article
- The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers.Cancers · 2021Review
- Contribution of Evolutionary Selected Immune Gene Polymorphism to Immune-Related Disorders: The Case of Lymphocyte Scavenger ReceptorsInternational journal of molecular sciences · 2021Review
- Interactions of ferritin with scavenger receptor class A members.The Journal of biological chemistry · 2020Article
- Structures of SALSA/DMBT1 SRCR domains reveal the conserved ligand-binding mechanism of the ancient SRCR fold.Life science alliance · 2020Article
- Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model.EJNMMI research · 2020Article
- Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166.Clinical & experimental metastasis · 2019Review
- Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.Frontiers in immunology · 2018Article
- CD6, a Rheostat-Type Signalosome That Tunes T Cell Activation.Frontiers in immunology · 2018Review
- Roles of microRNAs and RNA-Binding Proteins in the Regulation of Colorectal Cancer Stem Cells.Cancers · 2017Review
- Cell Adhesion Molecule CD166/ALCAM Functions Within the Crypt to Orchestrate Murine Intestinal Stem Cell Homeostasis.Cellular and molecular gastroenterology and hepatology · 2017Article
- Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Activated leukocyte cell adhesion molecule regulates the interaction between pancreatic cancer cells and stellate cells.Molecular medicine reports · 2016Article
- Structures of CD6 and Its Ligand CD166 Give Insight into Their Interaction.Structure (London, England : 1993) · 2015Article
- Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.Diagnostic pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
CD6 is a 130-kD glycoprotein expressed on the surface of thymocytes and peripheral blood T cells that is involved in TCR-mediated T cell activation. In thymus, CD6 mediates interactions between thymocytes and thymic epithelial (TE) cells. In indirect immunofluorescence assays, a recombinant CD6-immunoglobulin fusion protein (CD6-Rg) bound to cultured human TE cells and to thymic fibroblasts. CD6-Rg binding to TF and TE cells was trypsin sensitive, and 54 +/- 4% of binding was divalent cation dependent. By screening the blind panel of 479 monoclonal antibodies (mAbs) from the 5th International Workshop on Human Leukocyte Differentiation Antigens for expression on human TE cells and for the ability to block CD6-Rg binding to TE cells, we found one mAb (J4-81) that significantly inhibited the binding of CD6-Rg to TE cells (60 +/- 7% inhibition). A second mAb to the surface antigen identified by mAb J4-81, J3-119, enhanced the binding of CD6-Rg to TE cells by 48 +/- 5%. Using covalent cross-linking and trypsin digestion, we found that mAb J4-81 and CD6-Rg both bound to the same 100-kD glycoprotein (CD6L-100) on the surface of TE cells. These data demonstrate that a 100-kD glycoprotein on TE cells detected by mAb J4-81 is a ligand for CD6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.